Fig. 1

Overexpression of MUC16 in TNBC patients. A. Expression of MUC16 is highly upregulated in the poorly differentiated patients (N = 36) compared to moderately differentiated samples (N = 25). B. In silico TCGA-BRCA analysis indicating grade-wise expression of MUC16 transcript. C. Kaplan–Meier survival plot (https://kmplot.com) showing significant reduction in overall survival of breast cancer patients with high MUC16 (Q8WXI7) protein expression (220,196 probe was used to identify the MUC16 gene) D. Volcano plot of TCGA-BRCA dataset indicating high levels of MUC16 mRNA in breast cancer patients that have undergone chemotherapy compared to chemotherapy-naive patients. E. Box plot showing increased MUC16 expression in non-responders (any chemotherapy) compared to responders in breast cancer. F. AUC curve of MUC16 (220196_at) based on the 5-year relapse-free survival of breast cancer after any chemotherapy (http://www.rocplot.org). G. Box plots of IHC scores showing upregulation of MUC16 expression in TNBC patients compared to other breast cancer subtypes. H. Similarly, in silico dataset (TCGA-METABRIC) indicated upregulation of MUC16 in TNBC patients (N = 171) compared to HER2 (N = 78), Lum A (N = 499), and Lum B (N = 197)